MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine To guage many intravenous doses of sifalimumab, in Grownup people with dermatomyositis or polymyositis (NCT00533091). Main trial objectives have been To guage the protection and tolerability of sifalimumab in dermatomyositis or polymyositis individuals, although one of the explor... https://russello887bny0.wikiinside.com/user